U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

James N, Pirrie S, Liu W, et al. Image directed redesign of bladder cancer treatment pathways: the BladderPath RCT. Southampton (UK): National Institute for Health and Care Research; 2024 Aug. (Health Technology Assessment, No. 28.42.)

Cover of Image directed redesign of bladder cancer treatment pathways: the BladderPath RCT

Image directed redesign of bladder cancer treatment pathways: the BladderPath RCT.

Show details

References

1.
CRUK Cancerstats: Bladder Cancer. 2014. URL: www​.cancerresearchuk​.org/cancer-info/cancerstats​/types/bladder/ (accessed 22 April 2014).
2.
Bessa A, Maclennan S, Enting D, Bryan R, Josephs D, Hughes S, et al. Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method. Eur Urol 2019;76(2):258–9. [PubMed: 30712969]
3.
Bryan RT, Kirby R, O’Brien T, Mostafid H. So much cost, such little progress. Eur Urol 2014;66(2):263–4. [PubMed: 24598013]
4.
Kaplan AL, Litwin MS, Chamie K. The future of bladder cancer care in the USA. Nat Rev Urol 2014;11(1):59–62. [PubMed: 23979659]
5.
Kulkarni GS, Hakenberg OW, Gschwend JE, Thalmann G, Kassouf W, Kamat A, Zlotta A. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol 2010;57(1):60–70. [PubMed: 19740595]
6.
Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL, et al. EAU guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol 2022;81(1):75–94. [PubMed: 34511303]
7.
Woldu SL, Bagrodia A, Lotan Y. Guideline of guidelines: non-muscle-invasive bladder cancer. BJU Int 2017;119(3):371–80. [PMC free article: PMC5315602] [PubMed: 28058776]
8.
Witjes JA, Bruins HM, Cathomas R, Compérat EM, Cowan NC, Gakis G, et al. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol 2021;79(1):82–104. [PubMed: 32360052]
9.
Engilbertsson H, Aaltonen KE, Bjornsson S, Kristmundsson T, Patschan O, Rydén L, Gudjonsson S. Transurethral bladder tumor resection can cause seeding of cancer cells into the bloodstream. J Urol 2014;193:53–7. [PubMed: 24996129]
10.
Maurer T, Souvatzoglou M, Kubler H, Opercan K, Schmidt S, Herrmann K, et al. Diagnostic efficacy of [11C]choline positron emission tomography/computed tomography compared with conventional computed tomography in lymph node staging of patients with bladder cancer prior to radical cystectomy. Eur Urol 2012;61(5):1031–8. [PubMed: 22196847]
11.
Rajesh A, Sokhi HK, Fung R, Mulcahy KA, Bankart MJ. Bladder cancer: evaluation of staging accuracy using dynamic MRI. Clin Radiol 2011;66(12):1140–5. [PubMed: 21924408]
12.
Swinnen G, Maes A, Pottel H, Vanneste A, Billiet I, Lesage K, Werbrouck P. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur Urol 2010;57(4):641–7. [PubMed: 19477579]
13.
Vargas HA, Akin O, Schoder H, Olgac S, Dalbagni G, Hricak H, Bochner BH. Prospective evaluation of MRI, (1)(1)C-acetate PET/CT and contrast-enhanced CT for staging of bladder cancer. Eur J Radiol 2012;81(12):4131–7. [PubMed: 22858427]
14.
Russell B, Liedberg F, Khan MS, Nair R, Thurairaja R, Malde S, et al. A systematic review and meta-analysis of delay in radical cystectomy and the effect on survival in bladder cancer patients. Eur Urol Oncol 2020;3(2):239–49. [PubMed: 31668714]
15.
Fahmy NM, Mahmud S, Aprikian AG. Delay in the surgical treatment of bladder cancer and survival: systematic review of the literature. Eur Urol 2006;50(6):1176–82. [PubMed: 16846680]
16.
Kulkarni GS, Urbach DR, Austin PC, Fleshner NE, Laupacis A. Longer wait times increase overall mortality in patients with bladder cancer. J Urol 2009;182(4):1318–24. [PubMed: 19683272]
17.
Mahmud SM, Fong B, Fahmy N, Tanguay S, Aprikian AG. Effect of preoperative delay on survival in patients with bladder cancer undergoing cystectomy in Quebec: a population based study. J Urol 2006;175(1):78–83; discussion 83. [PubMed: 16406875]
18.
Mowatt G, Zhu S, Kilonzo M, Boachie C, Fraser C, Griffiths TRL, et al. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess 2010;14(4):1–331, iii–iv. [PubMed: 20082749]
19.
Boustead GB, Fowler S, Swamy R, Kocklebergh R, Hounsome L; Section of Oncology, BAUS. Stage, grade and pathological characteristics of bladder cancer in the UK: British Association of Urological Surgeons (BAUS) Urological Tumour Registry. BJU Int 2014;113(6):924–30. [PubMed: 24447825]
20.
Bryan RT, Zeegers MP, van Roekel EH, Bird D, Grant MR, Dunn JA, et al. A comparison of patient and tumour characteristics in two UK bladder cancer cohorts separated by 20 years. BJU Int 2013;112(2):169–75. [PubMed: 23452262]
21.
Meeks JJ, Herr HW. Office-based management of nonmuscle invasive bladder cancer. Urol Clin North Am 2013;40(4):473–9. [PubMed: 24182970]
22.
Panebianco V, Narumi Y, Altun E, Bochner BH, Efstanthiou JA, Hafeez S, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol 2018;74(3):294–306. [PMC free article: PMC6690492] [PubMed: 29755006]
23.
Del Giudice F, Flammia RS, Pecoraro M, Moschini M, D’Andrea D, Messina E, et al. The accuracy of Vesical Imaging-Reporting and Data System (VI-RADS): an updated comprehensive multi-institutional, multi-readers systematic review and meta-analysis from diagnostic evidence into future clinical recommendations. World J Urol 2022;40(7):1617–28. [PMC free article: PMC9237003] [PubMed: 35294583]
24.
Del Giudice F, Barchetti G, De Berardinis E, Pecoraro M, Salvo V, Simone G, et al. Prospective assessment of Vesical Imaging Reporting and Data System (VI-RADS) and its clinical impact on the management of high-risk non-muscle-invasive bladder cancer patients candidate for repeated transurethral resection. Eur Urol 2020;77(1):101–9. [PubMed: 31699526]
25.
Bouchelouche K. PET/CT in bladder cancer: an update. Semin Nucl Med 2022;52(4):475–85. [PubMed: 34996595]
26.
Bouchelouche K, Turkbey B, Choyke PL. PET/CT and MRI in bladder cancer. J Cancer Sci Ther 2012;S14(1):7692. [PMC free article: PMC3587689] [PubMed: 23471167]
27.
Takeuchi M, Sasaki S, Ito M, Okada S, Takahashi S, Kawai T, et al. Urinary bladder cancer: diffusion-weighted MR imaging: accuracy for diagnosing T stage and estimating histologic grade. Radiology 2009;251(1):112–21. [PubMed: 19332849]
28.
Donaldson SB, Bonington SC, Kershaw LE, Cowan R, Lyons J, Elliott T, Carrington BM. Dynamic contrast-enhanced MRI in patients with muscle-invasive transitional cell carcinoma of the bladder can distinguish between residual tumour and post-chemotherapy effect. Eur J Radiol 2013;82(12):2161–8. [PubMed: 24034835]
29.
Takeuchi M, Sasaki S, Naiki T, Kawai N, Kohri K, Hara M, Shibamoto Y. MR imaging of urinary bladder cancer for T-staging: a review and a pictorial essay of diffusion-weighted imaging. J Magnet Reson Imaging 2013;38(6):1299–309. [PubMed: 24265260]
30.
Ward DG, Baxter L, Ott S, Gordon NS, Wang J, Patel P, et al.; BladderPath Trial Management Group. Highly sensitive and specific detection of bladder cancer via targeted ultra-deep sequencing of urinary DNA. Eur Urol Oncol 2023;6(1):67–75. [PubMed: 35410825]
31.
Ward DG, Gordon NS, Boucher RH, Pirrie SJ, Baxter L, Ott S, et al. Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification. BJU Int 2019;124(3):532–44. [PMC free article: PMC6772022] [PubMed: 31077629]
32.
Stenzl A, Cowan NC, De Santis M, Jakse G, Kuczyk MA, Merseburger AS, et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2009;55(4):815–25. [PubMed: 19157687]
33.
Rosenkrantz AB, Haghighi M, Horn J, Naik M, Hardie AD, Somberg MB, et al. Utility of quantitative MRI metrics for assessment of stage and grade of urothelial carcinoma of the bladder: preliminary results. AJR Am J Roentgenol 2013;201(6):1254–9. [PubMed: 24261364]
34.
Rosenkrantz AB, Mussi TC, Melamed J, Taneja SS, Huang WC. Bladder cancer: utility of MRI in detection of occult muscle-invasive disease. Acta Radiol 2012;53(6):695–9. [PubMed: 22637641]
35.
Bryan RT, Collins SI, Daykin MC, Zeegers MP, Cheng KK, Wallace DMA, et al. Mechanisms of recurrence of Ta/T1 bladder cancer. Ann Royal Coll Surg Engl 2010; 92(6): 519-24. [PMC free article: PMC3182798] [PubMed: 20522307]
36.
Wilby D, Thomas K, Ray E, Chappell B, O’Brien T. Bladder cancer: new TUR techniques. World J Urol 2009;27(3):309–12. [PubMed: 19259684]
37.
Begum G, Dunn JA, Bryan RT, Bathers S, Wallace DM; West Midlands Urological Research Group. Socio-economic deprivation and survival in bladder cancer. BJU Int 2004;94(4):539–43. [PubMed: 15329108]
38.
Bryan RT, Liu W, Pirrie SJ, Amir R, Gallagher J, Hughes AI, et al. Comparing an imaging-guided pathway with the standard pathway for staging muscle-invasive bladder cancer: preliminary data from the BladderPath study. Eur Urol 2021;80(1):12–5. [PubMed: 33653635]
39.
Lynch TH, Waymont B, Dunn JA, Hughes MA, Wallace DM. Rapid diagnostic service for patients with haematuria. Br J Urol 1994;73(2):147–51. [PubMed: 8131015]
40.
41.
Bellmunt J, Kim J, Reardon B, Perera-Bel J, Orsola A, Rodriguez-Vida A, et al. Genomic predictors of good outcome, recurrence or progression in High grade T1 non-muscle invasive bladder cancer. Cancer Res 2020;80:4476–86. [PMC free article: PMC9361191] [PubMed: 32868381]
42.
Pietzak E, Bagrodia A, Cha E, Drill EN, Iyer G, Isharwal S, et al. Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets. Eur Urol 2017;72:952–9. [PMC free article: PMC6007852] [PubMed: 28583311]
43.
Mintz HP, Dosanjh A, Parsons HM, Hughes A, Jakeman A, Pope AM, Bryan RT, et al. Development and validation of a follow-up methodology for a randomised controlled trial, utilising routine clinical data as an alternative to traditional designs: a pilot study to assess the feasibility of use for the BladderPath trial. Pilot Feasibil Stud 2020;6:165. [PMC free article: PMC7599120] [PubMed: 33292682]
44.
Mintz HP, Dosanjh A, Parsons HM, Matthew S, Bryan RT, James NJ, Patel P. Making administrative healthcare systems clinical data the future of clinical trials: lessons from BladderPath. BMJ Oncol 2023;2:e000038.
45.
Chu AT, Holt SK, Wright JL, Ramos JD, Grivas P, Yu EY, Gore JL. Delays in radical cystectomy for muscle-invasive bladder cancer. Cancer 2019;125(12):2011–7. [PubMed: 30840335]
46.
Cancer Alliance Data Evidence and Analysis Service (CADEAS). Median Pathway Analysis by Patient Demographics, Stage at Diagnosis, Route to Diagnosis, and Geography. 2018. URL: www​.cancerdata.nhs.uk​/median_pathways/tool (accessed 9 February 2023).
47.
Hanna TP, King WD, Thibodeau S, Jalink M, Paulin GA, Harvey-Jones E, et al. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ 2020;371:m4087. [PMC free article: PMC7610021] [PubMed: 33148535]
48.
Wallace DM, Bryan RT, Dunn JA, Begum G, Bathers S. Delay and survival in bladder cancer. BJU Int 2002;89(9):868–78. [PubMed: 12010230]
49.
Gore JL, Lai J, Setodji CM, Litwin MS, Saigal CS; Urologic Diseases in America Project. Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a surveillance, epidemiology, and end results-Medicare analysis. Cancer 2009;115(5):988–96. [PMC free article: PMC2654713] [PubMed: 19142878]
50.
Lee CT, Madii R, Daignault S, Dunn RL, Zhang Y, Montie JE, Wood DP. Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival. J Urol 2006;175(4):1262–7; discussion 1267. [PubMed: 16515975]
51.
Beer E. Landmark article May 28, 1910: removal of neoplasms of the urinary bladder By Edwin Beer. JAMA 1983;250(10):1324–5. [PubMed: 6348311]
52.
Kulkarni GS, Hermanns T, Wei Y, Bhindi B, Satkunasivam R, Athanasopoulos P, et al. Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic. J Clin Oncol 2017;35(20):2299–305. [PubMed: 28410011]
53.
Cai T, Tiscione D, Verze P, Pomara G, Racioppi M, Nesi G, et al. Concordance and clinical significance of uncommon variants of bladder urothelial carcinoma in transurethral resection and radical cystectomy specimens. Urology 2014;84(5):1141–6. [PubMed: 25239253]
54.
Lonati C, Baumeister P, Ornaghi PI, Di Trapani E, De Cobelli O, Rink M, et al.; EAU-YAU Urothelial Cancer Working Party. Accuracy of transurethral resection of the bladder in detecting variant histology of bladder cancer compared with radical cystectomy. Eur Urol Focus 2022;8(2):457–64. [PubMed: 33867307]
55.
Catto JWF, Gordon K, Collinson M, Poad H, Twiddy M, Johnson M, et al.; BRAVO Study Group. Radical cystectomy against intravesical BCG for high-risk high-grade nonmuscle invasive bladder cancer: results from the randomized controlled BRAVO-feasibility study. J Clin Oncol 2021;39(3):202–14. [PMC free article: PMC8078404] [PubMed: 33332191]
56.
Brausi M, Collette L, Kurth K, van der Meijden AP, Oosterlinck W, Witjes JA, et al.; EORTC Genito-Urinary Tract Cancer Collaborative Group. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 2002;41(5):523–31. [PubMed: 12074794]
57.
Schober JP, Plimack E, Geynisman DM, Zibelman M. The past, present, and future of pT0 in bladder cancer clinical trials. Curr Opin Urol 2022;32(5):495–9. [PubMed: 35855573]
58.
Lindskrog SV, Prip F, Lamy P, Taber A, Groeneveld CS, Birkenkamp-Demtröder K, et al. An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nat Commun 2021;12(1):2301. [PMC free article: PMC8052448] [PubMed: 33863885]
59.
Awasthi S, Grass GD, Torres-Roca J, Johnstone PAS, Pow-Sang J, Dhillon J, et al. Genomic testing in localized prostate cancer can identify subsets of African-Americans with aggressive disease. J Natl Cancer Inst 2022;114:1656–64. [PMC free article: PMC9745424] [PubMed: 36053178]
60.
Christensen E, Birkenkamp-Demtroder K, Sethi H, Shchegrova S, Salari R, Nordentoft I, et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J Clin Oncol 2019;37(18):1547–57. [PubMed: 31059311]
61.
Vandekerkhove G, Lavoie JM, Annala M, Murtha AJ, Sundahl N, Walz S, et al. Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. Nat Commun 2021;12(1):184. [PMC free article: PMC7794518] [PubMed: 33420073]
62.
During VA, Sole GM, Jha AK, Anderson JA, Bryan RT. Prediction of histological stage based on cytoscopic appearances of newly diagnosed bladder tumours. Ann R Coll Surg Engl 2016;98(8):547–51. [PMC free article: PMC5392893] [PubMed: 27502337]
63.
Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer – 2020 Update Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 2021;79(2):243–62. [PubMed: 33172724]
64.
Eldred-Evans D, Connor MJ, Bertoncelli Tanaka M, Bass E, Reddy D, Walters U, et al. The rapid assessment for prostate imaging and diagnosis (RAPID) prostate cancer diagnostic pathway. BJU Int 2023;131(4):461–70. [PubMed: 36134435]
65.
Dyer T, Siemens DR, Nippak P, Meyer J, Booth CM. Histology at transurethral resection of bladder tumor and radical cystectomy for bladder cancer: insights from population-based data. Can Urol Assoc J 2021;15(4):138–40. [PMC free article: PMC8021414] [PubMed: 33007186]
Copyright © 2024 James et al.

This work was produced by James et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.

Bookshelf ID: NBK606781
Contents

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (1.9M)

Other titles in this collection

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...